Sanofi US News

Repeated Doctors Visits, ER Trips, and Admissions to Inpatient/Outpatient Facilities Create High Costs for Managing Patients with a Common, Complex Cardiovascular Disease

-'Diabetes Co-Stars' Offers Information and Support to People Living with Diabetes, Family and Friends -

- Findings Presented at European Association for the Study of Diabetes (EASD) 46th Annual Meeting -

- Phase III Study Results also demonstrated the therapy had acceptable safety profile -

Hundreds of thousands of doses of vaccine and medical supplies also provided

- Funding supports programs to advance personalized medicine -

- 1-vial Taxotere offers simplified preparation -

Early shipments support national goal to increase immunization rates

- Study Findings Presented at American Diabetes Association's 70th Annual Scientific Sessions -

- Study Results Presented at American Diabetes Association's 70th Annual Scientific Sessions -

- First and only therapy to provide significant survival benefit in second-line metastatic hormone-refractory prostate cancer -

- Alliance formed to advance cutting-edge research and foster collaboration between academia and industry -

- Sanofi-aventis Supports Consortium's Activities to Fund Promising Early-Stage Life Sciences Companies -

The licensed technology was developed by the NMRC with the help of the University of Colorado

Interactive Exhibit Unveiled at New Jersey's Liberty Science Center as it Embarks on Three-Year, 12-City Tour

Chattem Becomes the U.S. Consumer Healthcare Platform for sanofi-aventis

- Results observed in patients treated with cabazitaxel plus prednisone whose disease progressed despite prior docetaxel-based chemotherapy -

The Coalition to Prevent DVT Sends Awareness into Motion with an Educational Program Focusing on Preventative Care Through Movement

New Data Published by Journal of American Academy of Dermatology Demonstrated Sustained Efficacy Up to 25 Months

"AFib Support Team" Offers Insights on Comprehensive Approach to Management of Serious Heart Condition

Fluzone® High-Dose (Influenza Virus Vaccine) strengthens immune response in the 65+ population, an age group that suffers disproportionately from influenza and its complications

-- Combination Strengthens sanofi-aventis' Strategy to Accelerate Growth Through Innovation, Geographic Expansion and External Growth

Novel vaccine approach tested against one of the most common causes of hospital-acquired infection in Europe and North America

- Atul Dhir, M.D., Ph.D. has been appointed new BiPar CEO to continue growing entrepreneurial and innovative culture -

Final data confirm immunogenicity, safety profile

The two-dose meningococcal quadrivalent conjugate vaccine was generally well-tolerated

- Elitek is now approved to manage a potentially life-threatening complication associated with anti-cancer treatment in adults -

The first clinical trial data from America’s youngest vaccine recipients, children 6 months through 9 years of age, show the vaccine induces an immune response and is well-tolerated

Taking Control of Your Diabetes (TCOYD) Calls on Marketing Leaders and Creative Minds to "Start Taking Action Now for Diabetes"

Data from studies in adults 18 years of age and older provide confirmation that one dose of vaccine produces a robust immune response even in those over the age of 65 years

Women may delay treatment or seek injectable procedures

Company has now committed to produce 75.3 million doses of vaccine for the U.S. government